好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Delayed-Start Analyses of Solanezumab Phase 3 Studies in Mild Alzheimer’s Disease
Aging, Dementia, and Behavioral Neurology
(-)
108
Authors/Disclosures

PRESENTER
No disclosure on file
Scott W. Andersen Scott W. Andersen has received personal compensation for serving as an employee of Eli Lilly. Scott W. Andersen has stock in Eli Lilly. Scott W. Andersen has received personal compensation in the range of $100,000-$499,999 for serving as a Statistician with Eli Lilly.
No disclosure on file
Eric R. Siemers, MD (Siemers Integration LLC) Dr. Siemers has received personal compensation for serving as an employee of Acumen Pharmaceuticals. The institution of Dr. Siemers has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for Vaccinex Pharmceuticals. The institution of Dr. Siemers has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for Gates Ventures LLC. Dr. Siemers has or had stock in Acumen Pharmaceuticals.Dr. Siemers has or had stock in Ell Lilly and Company.Dr. Siemers has received personal compensation in the range of $0-$499 for serving as a study section reviewer with National Institutes of Health. Dr. Siemers has a non-compensated relationship as a Volunteer with Alzheimer's Association that is relevant to AAN interests or activities.